Ceftazidime Safety and Efficacy in the Prevention of Surgical Site Infections
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07934199. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ceftazidime Safety and Efficacy in the Prevention of Surgical Site Infections in Thoracolumbar Spinal Surgery
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The research team hypothesizes that ceftazidime, in conjunction with vancomycin, is a safe and effective way to prevent surgical site infections in lumbar spinal surgery. Objective 1: Evaluate the drain and serum concentrations of ceftazidime + vancomycin from 0-3 days postoperative. Hypothesis: The investigators hypothesize that intrawound ceftazidime will remain concentrated at the wound site, and there will be minimal absorption of ceftazidime into the circulatory system. Objective 2: Evaluate incidence of surgical site infections (within 90 days postoperative) and pseudoarthrosis (within 2 years postoperative) after the use of ceftazidime in addition to vancomycin. Hypothesis: The investigators hypothesize that intrawound ceftazidime, in conjunction with intrawound vancomycin, is a safe and effective way to reduce surgical site infections following lumbar spine surgery, while having little effect on construct fusion (e.g., pseudoarthrosis). Objective 3: Evaluate ceftazidime concentration effects on osteoblasts, specifically metabolic activity and osteogenic protein expression profiles. Hypothesis: The investigators hypothesize that ceftazidime concentrations measured from drain samples will not have an effect on metabolic activity and osteogenic protein expression of osteoblasts.
Study identification
- NCT ID
- NCT07934199
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2026 (Actual)
- Primary completion
- Jul 2030 (Estimated)
- Completion
- Jul 2030 (Estimated)
- Last update posted
- Nov 12, 2026
2026 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Utah Orthopedics | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07934199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2026 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.